![Daniel Germann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Daniel Germann
Amministratore Delegato presso Kantonsspital St.Gallen
Profilo
Daniel Germann currently works at Kantonsspital St.Gallen, as Chairman-Management Board from 2010.
Posizioni attive di Daniel Germann
Società | Posizione | Inizio |
---|---|---|
Kantonsspital St.Gallen
![]() Kantonsspital St.Gallen Hospital/Nursing ManagementHealth Services Kantonsspital St.Gallen is a major tertiary referral center for eastern Switzerland and one of the largest hospitals in the region. The hospital is based in St. Gallen, Switzerland, and is a combination of St. Gallen, Rorschach, and Flawil hospitals, offering a wide range of high-quality services to ensure the medical basic and special care of eastern Switzerland. With over 6,000 employees, the hospital is committed to providing evidence-based care and treatment to its patients. The hospital also conducts strong basic, translational, and clinical research to offer patients access to validated interventions and novel treatments. Daniel Germann has been the CEO of the Swiss company since 1998. | Amministratore Delegato | 01/05/2010 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Kantonsspital St.Gallen
![]() Kantonsspital St.Gallen Hospital/Nursing ManagementHealth Services Kantonsspital St.Gallen is a major tertiary referral center for eastern Switzerland and one of the largest hospitals in the region. The hospital is based in St. Gallen, Switzerland, and is a combination of St. Gallen, Rorschach, and Flawil hospitals, offering a wide range of high-quality services to ensure the medical basic and special care of eastern Switzerland. With over 6,000 employees, the hospital is committed to providing evidence-based care and treatment to its patients. The hospital also conducts strong basic, translational, and clinical research to offer patients access to validated interventions and novel treatments. Daniel Germann has been the CEO of the Swiss company since 1998. | Health Services |
- Borsa valori
- Insiders
- Daniel Germann